Key result
TREiNOX reduces profibrotic markers and boosts VEGF release in diabetic and metabolic syndrome cardiac cells.
Why the study?
Metabolic syndrome and type 2 diabetes mellitus adversely affect cardiac stromal cell fibrotic commitment via oxidative state and autophagy, prompting research to characterize these cells and reverse this commitment.
Does pharmacological modulation of oxidative state and autophagy restore normal biological features in human cardiac stromal cells from dysmetabolic patients?
Does pharmacological modulation of oxidative state and autophagy restore normal biological features in human cardiac stromal cells from dysmetabolic patients?
Pharmacological targeting of autophagy and oxidative stress can partially reverse the profibrotic and antiangiogenic phenotype of human cardiac stromal cells exposed to dysmetabolic conditions.
Answers are grounded in this paper and cite their sources.
TREiNOX may reverse profibrotic features in dysmetabolic cardiac cells; leaves open clinical translation pending in vivo validation.
Cardiac stromal cells (CSCs) are the main players in fibrosis. Dysmetabolic conditions (metabolic syndrome—MetS, and type 2 diabetes mellitus—DM2) are strong pathogenetic contributors to cardiac fibrosis. Moreover, modulation of the oxidative state (OxSt) and autophagy is a fundamental function affecting the fibrotic commitment of CSCs, that are adversely modulated in MetS/DM2. We aimed to characterize CSCs from dysmetabolic patients, and to obtain a beneficial phenotypic setback from such fibrotic commitment by modulation of OxSt and autophagy. CSCs were isolated from 38 patients, stratified as MetS, DM2, or controls. Pharmacological modulation of OxSt and autophagy was obtained by treatment with trehalose and NOX4/NOX5 inhibitors (TREiNOX). Flow‐cytometry and real‐time quantitative polymerase chain reaction (RT‐qPCR) analyses showed significantly increased expression of myofibroblasts markers in MetS‐CSCs at baseline ( GATA4, ACTA2, THY1 /CD90) and after starvation ( COL1A1, COL3A1 ). MetS‐ and DM2‐CSCs displayed a paracrine profile distinct from control cells, as evidenced by screening of 30 secreted cytokines, with a significant reduction in vascular endothelial growth factor (VEGF) and endoglin confirmed by enzyme‐linked immunoassay (ELISA). DM2‐CSCs showed significantly reduced support for endothelial cells in angiogenic assays, and significantly increased H 2 O 2 release and NOX4/5 expression levels. Autophagy impairment after starvation (reduced ATG7 and LC3‐II proteins) was also detectable in DM2‐CSCs. TREiNOX treatment significantly reduced ACTA2, COL1A1, COL3A1 , and NOX4 expression in both DM2‐ and MetS‐CSCs, as well as GATA4 and THY1 /CD90 in DM2, all versus control cells. Moreover, TREiNOX significantly increased VEGF release by DM2‐CSCs, and VEGF and endoglin release by both MetS‐ and DM2‐CSCs, also recovering the angiogenic support to endothelial cells by DM2‐CSCs. In conclusion, DM2 and MetS worsen microenvironmental conditioning by CSCs. Appropriate modulation of autophagy and OxSt in human CSCs appears to restore these features, mostly in DM2‐CSCs, suggesting a novel strategy against cardiac fibrosis in dysmetabolic patients.
No takes yet. Share an insight, caveat, or question.
Pagano et al. (2022) studied Ischemic cardiomyopathy with or without dysmetabolism (Metabolic Syndrome or Type 2 Diabetes Mellitus) (n=38). TREiNOX (trehalose + GKT137831 + KN-93) vs. Untreated control cells was evaluated on Expression of myofibroblast markers and proangiogenic capacity. TREiNOX treatment significantly reduced expression of profibrotic markers and increased VEGF release in cardiac stromal cells from DM2 and MetS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: